C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.530
-0.120 (-4.53%)
At close: Nov 17, 2026, 4:00 PM EST
2.520
-0.010 (-0.40%)
After-hours: Nov 17, 2026, 7:41 PM EST

C4 Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
32.2835.9535.5820.7631.145.79
Revenue Growth
7.20%1.02%71.44%-33.25%-32.08%37.93%
Cost of Revenue
3.68.9812.54117.71117.8494.67
Gross Profit
28.6826.9723.05-96.95-86.75-48.88
Selling, General & Admin
35.3636.242.1242.0842.7933.25
Research & Development
95.2695.2698.1---
Operating Expenses
130.63131.46140.2242.0842.7933.25
Operating Income
-101.95-104.49-117.18-139.03-129.53-82.13
Interest Expense
----1.37-2.22-2.15
Interest & Investment Income
8.387.619.036.034.292.27
EBT Excluding Unusual Items
-93.57-96.88-108.14-134.38-127.46-82.01
Merger & Restructuring Charges
---2.44---
Gain (Loss) on Sale of Investments
2.62.745.43.78-0.71-1.88
Asset Writedown
--10.73----
Other Unusual Items
----0.62--
Pretax Income
-90.97-104.87-105.19-131.21-128.18-83.89
Income Tax Expense
0.120.120.131.28--
Net Income
-91.09-104.99-105.32-132.49-128.18-83.89
Net Income to Common
-91.09-104.99-105.32-132.49-128.18-83.89
Net Income Growth
------
Shares Outstanding (Basic)
1288369504946
Shares Outstanding (Diluted)
1288369504946
Shares Change
78.97%19.49%39.75%1.59%6.13%304.93%
EPS (Basic)
-0.71-1.27-1.52-2.67-2.62-1.82
EPS (Diluted)
-0.71-1.27-1.52-2.67-2.62-1.82
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-79.74-99.3-65.34-108.55-111.44-88.24
Free Cash Flow Per Share
-0.63-1.20-0.94-2.19-2.28-1.92
Gross Margin
88.85%75.03%64.76%--278.96%-106.76%
Operating Margin
-315.86%-290.68%-329.30%-669.83%-416.56%-179.39%
Profit Margin
-282.22%-292.08%-295.96%-638.34%-412.19%-183.23%
Free Cash Flow Margin
-247.05%-276.24%-183.61%-522.96%-358.36%-192.73%
EBITDA
-100.51-102.53-115.36-137.15-127.86-80.64
EBITDA Margin
--285.23%----176.13%
D&A For EBITDA
1.441.961.821.881.681.49
EBIT
-101.95-104.49-117.18-139.03-129.53-82.13
EBIT Margin
--290.68%----179.39%
SEC Filings: 10-K · 10-Q